Core Insights - The National Health Commission of China announced that the probiotic strain YLGB-1496, developed by the National Dairy Technology Innovation Center in collaboration with Yili, has been included in the list of probiotics suitable for infant food, marking the first domestically developed strain for this purpose in China [1][3] Group 1: Industry Impact - The approval of YLGB-1496 represents a significant breakthrough for the domestic probiotic industry in China, reducing reliance on imported probiotics for infants [3] - YLGB-1496 is designed to efficiently utilize human milk oligosaccharides (HMO), which are crucial for the gut microbiota of breastfed infants, thus helping to establish a healthy early gut microecological system [3] Group 2: Research and Development - A series of rigorous clinical studies on infants have been conducted by Yili in collaboration with the National Dairy Technology Innovation Center and other authoritative institutions, leading to the granting of 15 Chinese invention patents related to this strain and its technology [3][4] Group 3: Commercialization - Jinqi Biotechnology, a platform under Yili with a national-level probiotic industrialization production demonstration line, is responsible for the industrialization and commercialization of YLGB-1496, supporting the upgrade of the health food industry towards high quality and diversification [4] - The strain has already been successfully applied in various products, including QQ Star's "Jianhu Mama," Jinhu Cheese Sticks, and Meiyitian Mixed Fruit and Vegetable Juice, with plans for broader application in infant formula and other core product lines [4]

Core Insights - YLGB-1496, a probiotic strain developed by Yili, has been included in the list of probiotics approved for infant food by the National Health Commission of China, marking a significant breakthrough in the domestic probiotic industry [1][3] Group 1: Probiotic Development - YLGB-1496 is the first probiotic strain in the list that is independently developed by a Chinese dairy company and derived from healthy human breast milk [1][3] - The strain is designed to be more compatible with the physical needs of Chinese infants, providing a tailored probiotic solution [1][3] Group 2: Scientific Validation - Clinical studies conducted in collaboration with the National Dairy Technology Innovation Center have shown that YLGB-1496 significantly reduces the incidence of eczema and respiratory infections in infants, aiding in the development of their immune systems [3] - The strain has also been proven to enhance gut comfort in infants, reducing the occurrence and severity of diarrhea symptoms [3] Group 3: Commercialization and Future Plans - Yili's subsidiary, Jinqi Biotechnology, is responsible for the industrial production and commercialization of YLGB-1496, supporting the upgrade of the health food industry towards high quality and diversification [4] - The strain has already been incorporated into several products, including QQ Star's maternal care products and mixed fruit and vegetable juices, with plans for broader application in infant formula [4] - The approval of YLGB-1496 signifies a major leap for China's dairy industry from technology following to independent innovation in the probiotic sector [4]

Core Insights - YLGB-1496, a probiotic strain developed by Yili, has been included in the list of probiotics approved for infant food by the National Health Commission of China, marking a significant breakthrough in the domestic probiotic industry [1][5] Group 1: Probiotic Development - YLGB-1496 is the first probiotic strain in the list that is independently developed by a Chinese dairy company and derived from Chinese breast milk [1][5] - The strain is designed to be more compatible with the physical needs of Chinese infants, providing a tailored probiotic solution [1][4] Group 2: Health Benefits - Clinical studies conducted in collaboration with the National Dairy Technology Innovation Center have shown that YLGB-1496 significantly reduces the incidence of eczema and respiratory infections in infants, aiding in the development of their immune systems [5] - The strain has also been proven to enhance gut comfort in infants, reducing the occurrence and severity of diarrhea [5] Group 3: Industrialization and Product Application - Yili's subsidiary, Jinqi Biotechnology, is responsible for the industrialization and commercialization of YLGB-1496, ensuring high-quality and diverse probiotic products for the health food industry [6] - The strain has already been incorporated into several products, including QQ Star's maternal care products and mixed fruit and vegetable juices, with plans for further applications in infant formula [6] Group 4: Future Prospects - The approval of YLGB-1496 signifies a major leap for the Chinese dairy industry from technology following to independent innovation in the probiotic sector [7] - Yili aims to continue its research on the functional properties of the strain and promote the transformation of scientific achievements into products, contributing to the high-quality development of the Chinese dairy industry [7]

Group 1: Company Overview and Performance - The company achieved a revenue of 2,025 million yuan in the first half of 2025, representing a year-on-year growth of 4.62% [2] - Net profit reached 82.41 million yuan, with a year-on-year increase of 6.65% [3] - The adjusted net profit (扣非净利润) was 79.33 million yuan, showing a growth of 6.40% [3] Group 2: New Product Introductions - The medical beauty product "肌素然" focuses on skin repair and anti-aging, utilizing peptides as a core component [3] - The smoking cessation product "乐速克" offers a comprehensive solution for smoking control, aiming to help smokers manage their cravings scientifically [3] - The probiotics business leverages over 20 years of local strain research experience, showcasing strong R&D capabilities and product innovation [3] Group 3: Strategic Initiatives and Market Expansion - The company has made significant moves in extending its industrial chain through the acquisition of 民生中科 (Shandong) and exploring overseas markets [4] - The strategy emphasizes maintaining focus on major products while pursuing synergies through acquisitions [4] - The overseas market is viewed as having substantial potential, with plans to integrate into local markets rather than merely engaging in trade [4] Group 4: Competitive Advantages and Market Position - "肌素然" differentiates itself with patented ingredients and innovative membrane materials, targeting the medical beauty market [4] - The smoking cessation product "乐速克" is recognized as a first-line medication in clinical guidelines, with a unique full-cycle service model [5] - The probiotics segment is driven by a multi-engine strategy, focusing on raw materials, ODM/OEM, and proprietary brands [6] Group 5: Research and Development Capabilities - The "炎黄菌株库" (Yanhua Strain Library) is a proprietary resource established to support the development of probiotics tailored to the Chinese population [7] - The library has been built over several years, with a focus on local strains and their health benefits, ensuring a strong foundation for future innovations [7]